Logo image of NAGE

NIAGEN BIOSCIENCE INC (NAGE) Stock Fundamental Analysis

NASDAQ:NAGE - Nasdaq - US1710774076 - Common Stock - Currency: USD

9.82  +0.09 (+0.92%)

After market: 9.7811 -0.04 (-0.4%)

Fundamental Rating

6

Taking everything into account, NAGE scores 6 out of 10 in our fundamental rating. NAGE was compared to 54 industry peers in the Life Sciences Tools & Services industry. While NAGE has a great health rating, its profitability is only average at the moment. NAGE is valued quite expensive, but it does show an excellent growth. These ratings would make NAGE suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year NAGE was profitable.
In the past year NAGE had a positive cash flow from operations.
NAGE had negative earnings in 4 of the past 5 years.
In multiple years NAGE reported negative operating cash flow during the last 5 years.
NAGE Yearly Net Income VS EBIT VS OCF VS FCFNAGE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M -30M

1.2 Ratios

With an excellent Return On Assets value of 17.34%, NAGE belongs to the best of the industry, outperforming 96.30% of the companies in the same industry.
NAGE has a better Return On Equity (25.49%) than 94.44% of its industry peers.
NAGE has a better Return On Invested Capital (17.27%) than 92.59% of its industry peers.
Industry RankSector Rank
ROA 17.34%
ROE 25.49%
ROIC 17.27%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
NAGE Yearly ROA, ROE, ROICNAGE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Profit Margin of NAGE (13.07%) is better than 85.19% of its industry peers.
NAGE's Operating Margin of 12.26% is fine compared to the rest of the industry. NAGE outperforms 72.22% of its industry peers.
The Gross Margin of NAGE (62.51%) is better than 83.33% of its industry peers.
In the last couple of years the Gross Margin of NAGE has grown nicely.
Industry RankSector Rank
OM 12.26%
PM (TTM) 13.07%
GM 62.51%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
NAGE Yearly Profit, Operating, Gross MarginsNAGE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

8

2. Health

2.1 Basic Checks

NAGE has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for NAGE has been increased compared to 1 year ago.
Compared to 5 years ago, NAGE has more shares outstanding
NAGE has a better debt/assets ratio than last year.
NAGE Yearly Shares OutstandingNAGE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
NAGE Yearly Total Debt VS Total AssetsNAGE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

An Altman-Z score of 17.33 indicates that NAGE is not in any danger for bankruptcy at the moment.
The Altman-Z score of NAGE (17.33) is better than 100.00% of its industry peers.
There is no outstanding debt for NAGE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 17.33
ROIC/WACC1.63
WACC10.57%
NAGE Yearly LT Debt VS Equity VS FCFNAGE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

NAGE has a Current Ratio of 3.66. This indicates that NAGE is financially healthy and has no problem in meeting its short term obligations.
NAGE has a Current ratio (3.66) which is in line with its industry peers.
A Quick Ratio of 3.12 indicates that NAGE has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.12, NAGE is in the better half of the industry, outperforming 61.11% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.66
Quick Ratio 3.12
NAGE Yearly Current Assets VS Current LiabilitesNAGE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1150.00% over the past year.
NAGE shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.18%.
The Revenue has been growing by 16.56% on average over the past years. This is quite good.
EPS 1Y (TTM)1150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)19.18%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%36.86%

3.2 Future

Based on estimates for the next years, NAGE will show a very strong growth in Earnings Per Share. The EPS will grow by 54.99% on average per year.
The Revenue is expected to grow by 22.20% on average over the next years. This is a very strong growth
EPS Next Y32.6%
EPS Next 2Y56.46%
EPS Next 3Y54.99%
EPS Next 5YN/A
Revenue Next Year27.01%
Revenue Next 2Y23.49%
Revenue Next 3Y22.2%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NAGE Yearly Revenue VS EstimatesNAGE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
NAGE Yearly EPS VS EstimatesNAGE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4 -0.6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

NAGE is valuated quite expensively with a Price/Earnings ratio of 46.76.
NAGE's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.41. NAGE is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 40.11, the valuation of NAGE can be described as expensive.
NAGE's Price/Forward Earnings ratio is in line with the industry average.
When comparing the Price/Forward Earnings ratio of NAGE to the average of the S&P500 Index (33.87), we can say NAGE is valued inline with the index average.
Industry RankSector Rank
PE 46.76
Fwd PE 40.11
NAGE Price Earnings VS Forward Price EarningsNAGE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

NAGE's Enterprise Value to EBITDA is on the same level as the industry average.
The rest of the industry has a similar Price/Free Cash Flow ratio as NAGE.
Industry RankSector Rank
P/FCF 39.58
EV/EBITDA 50.7
NAGE Per share dataNAGE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NAGE has a very decent profitability rating, which may justify a higher PE ratio.
NAGE's earnings are expected to grow with 54.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.43
PEG (5Y)N/A
EPS Next 2Y56.46%
EPS Next 3Y54.99%

More info and screens

0

5. Dividend

5.1 Amount

NAGE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NIAGEN BIOSCIENCE INC

NASDAQ:NAGE (8/11/2025, 8:00:01 PM)

After market: 9.7811 -0.04 (-0.4%)

9.82

+0.09 (+0.92%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)10-29 2025-10-29/amc
Inst Owners33.23%
Inst Owner ChangeN/A
Ins Owners0.01%
Ins Owner Change6.42%
Market Cap773.52M
Analysts85.45
Price Target15.42 (57.03%)
Short Float %6.76%
Short Ratio3.3
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)297.02%
Min EPS beat(2)252.87%
Max EPS beat(2)341.18%
EPS beat(4)4
Avg EPS beat(4)295.72%
Min EPS beat(4)100%
Max EPS beat(4)488.82%
EPS beat(8)8
Avg EPS beat(8)176.93%
EPS beat(12)11
Avg EPS beat(12)125.5%
EPS beat(16)13
Avg EPS beat(16)92.26%
Revenue beat(2)2
Avg Revenue beat(2)8.54%
Min Revenue beat(2)6.81%
Max Revenue beat(2)10.27%
Revenue beat(4)3
Avg Revenue beat(4)4.57%
Min Revenue beat(4)-4.88%
Max Revenue beat(4)10.27%
Revenue beat(8)4
Avg Revenue beat(8)0.77%
Revenue beat(12)5
Avg Revenue beat(12)-0.38%
Revenue beat(16)6
Avg Revenue beat(16)-0.79%
PT rev (1m)0.13%
PT rev (3m)67.53%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-39.99%
EPS NY rev (1m)0%
EPS NY rev (3m)11.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)4.04%
Valuation
Industry RankSector Rank
PE 46.76
Fwd PE 40.11
P/S 7.17
P/FCF 39.58
P/OCF 39.27
P/B 13.98
P/tB 14.06
EV/EBITDA 50.7
EPS(TTM)0.21
EY2.14%
EPS(NY)0.24
Fwd EY2.49%
FCF(TTM)0.25
FCFY2.53%
OCF(TTM)0.25
OCFY2.55%
SpS1.37
BVpS0.7
TBVpS0.7
PEG (NY)1.43
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 17.34%
ROE 25.49%
ROCE 21.87%
ROIC 17.27%
ROICexc 207.52%
ROICexgc 221.7%
OM 12.26%
PM (TTM) 13.07%
GM 62.51%
FCFM 18.11%
ROA(3y)-9.02%
ROA(5y)-25.18%
ROE(3y)-18.83%
ROE(5y)-52.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y2.12%
F-Score7
Asset Turnover1.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 19.42%
Cap/Sales 0.14%
Interest Coverage 250
Cash Conversion 140.47%
Profit Quality 138.55%
Current Ratio 3.66
Quick Ratio 3.12
Altman-Z 17.33
F-Score7
WACC10.57%
ROIC/WACC1.63
Cap/Depr(3y)21.85%
Cap/Depr(5y)22.95%
Cap/Sales(3y)0.27%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1150%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y32.6%
EPS Next 2Y56.46%
EPS Next 3Y54.99%
EPS Next 5YN/A
Revenue 1Y (TTM)19.18%
Revenue growth 3Y13.87%
Revenue growth 5Y16.56%
Sales Q2Q%36.86%
Revenue Next Year27.01%
Revenue Next 2Y23.49%
Revenue Next 3Y22.2%
Revenue Next 5YN/A
EBIT growth 1Y402.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year585.77%
EBIT Next 3Y156.77%
EBIT Next 5YN/A
FCF growth 1Y455.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y485.46%
OCF growth 3YN/A
OCF growth 5YN/A